Kodiak Sciences Set to Share Innovations at the 44th J.P. Morgan Healthcare Conference

Kodiak Sciences Takes Center Stage at Key Healthcare Conference

On January 12, 2026, Kodiak Sciences Inc. (Nasdaq: KOD), a pioneering biotechnology firm focused on retinal health, will present at the prestigious 44th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The presentation, led by the company’s senior management team, promises to be a pivotal moment for Kodiak as it showcases its commitment to developing cutting-edge therapeutic solutions for retina-related diseases.

With an array of innovative projects, Kodiak Sciences is dedicated to transforming the treatment landscape for severe ocular diseases that can lead to blindness. The company's ongoing clinical trials focus on next-generation retina medicines designed to address the needs of patients suffering from retinal vascular diseases and inflammatory macular edema.

Current Clinical Developments

Kodiak is currently advancing three late-stage clinical programs that aim to tackle critical issues in the ocular healthcare space. Central to its presentation at the conference will be updates on two of its promising candidates, Tarcocimab and KSI-501, both of which are in late-stage Phase 3 trials targeting retinal vascular diseases. These diseases represent a significant segment of the $15 billion anti-VEGF market, making Kodiak's involvement increasingly relevant as patients look for new therapeutic options. Expected data readouts may occur starting from Q1 2026, offering insights that could propel these treatments towards potential regulatory approval.

Additionally, the company is developing KSI-101, a bispecific protein also in late-stage clinical development, aimed at treating Macular Edema Secondary to Inflammation (MESI). The outcome data from the ongoing studies are anticipated in Q4 2026 and Q2 2027.

Engaging Stakeholders

Kodiak’s participation in the J.P. Morgan Healthcare Conference will provide an essential platform for engaging with investors, stakeholders, and industry leaders. The company intends to communicate its unwavering commitment to advancing research that directly confronts the leading causes of preventable blindness worldwide. Interested parties can follow the presentation via a live webcast, available on Kodiak’s official website. The recording will be accessible for an extended period after the event, ensuring that all interested individuals can benefit from this crucial information.

Looking Ahead

As Kodiak Sciences prepares for its keynote presentation at such a major industry event, it stands as a testament to the company’s efforts to innovate within the healthcare sphere. With a focus on developing transformative therapeutics in retinal medicine, Kodiak is not only influencing current treatment paradigms but is also shaping the future of how ocular diseases are addressed. Investors and healthcare professionals alike will be keeping a close watch on Kodiak’s advancements, and we look forward to the insights that will emerge from this highly anticipated interaction.

For more details about the company’s ongoing initiatives and to view the live broadcast, visit Kodiak’s website at ir.kodiak.com.

About Kodiak Sciences Inc.
Established with a vision to bring novel scientific advances to retina medicine, Kodiak Sciences Inc. has positioned itself as a noteworthy player in the biotechnology arena. Beyond its product pipeline, the company’s commitment to research and patient care remains at the forefront of its mission.